Corrected PDF

Files in this Data Supplement:

• Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data - A sentence in the Results section of the abstract <1> on page 1421 accidentally reversed the intended meaning of the data comparison for the primary end points of the study. It should read, “Results: The efficacy end point (a composite of 30-day mortality, reinfarction or refractory ischemia) was 12.2% with enoxaparin versus 16.0% with unfractionated heparin (p < 0.001); the combined end point of efficacy plus safety (a composite of 30-day mortality, reinfarction, refractory ischemia, intracranial hemorrhage ICH or major systemic bleeding) was 15.0% versus 18.0%, respectively (p = 0.003).”